Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00547365 · ADVERSE EVENTS

Adverse events

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction · Source last updated 2013-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
1%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Human Immune Globulin Intravenous (IGIV)

Therapeutic potential of human immune globulin intravenous (IGIV)in patients with cardiac-associated AL amyloidosis

0 / 100 / 10Not reported / Not reported

Group identifiers: EG000: Human Immune Globulin Intravenous (IGIV)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      event Groups
      1. description
        Therapeutic potential of human immune globulin intravenous (IGIV)in patients with cardiac-associated AL amyloidosis
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        10
        serious Num Affected
        0
        serious Num At Risk
        10
        title
        Human Immune Globulin Intravenous (IGIV)
      frequency Threshold
      1

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice